Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally and remains a major public health ...

AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies ...

Because of this, doctors usually start COPD patients with bronchodilators and other treatments like education and exercise programs before they prescribe inhaled steroids.

Learn about COPD medications, including bronchodilators, steroids, and combination treatments. Understand how they work, their side effects, and ways to manage COPD effectively.

Background: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been properly investigated. We therefore performed a randomized, double ...

To date, studies of patients with PIBO have evaluated only the acute effects of inhaled bronchodilators on lung function parameters, and none of those studies have evaluated the long-term impact that ...

Article citations More>> Nakajima, T., Kuroda, A., Tsuji, E. and Yoshida, M. (2002) Isocoumarins and Bronchodilators Containing Them. JP Patent, 2002-1610. has been cited by the following article: ...

The current concept of the mechanisms whereby bronchodilators can improve exercise tolerance in patients with COPD focuses on the ability to reduce the rate of increase in end-expiratory lung volume ...

Background: Studies examining the physiological interactions of oxygen (O2) and bronchodilators (BD) during exercise in chronic obstructive pulmonary disease (COPD) should provide new insights into ...

It is possible that in some patients conservative treatment consisting of rest, bronchodilators, antibiotics and postural drainage would achieve equally good results.

Treatment guidelines for COPD consider long-acting bronchodilators as a class and make no distinction between anticholinergic drugs and long-acting β agonists (LABAs), resulting in clinical equipoise.

Chronic Bronchitis Market Expected to Grow at a CAGR of 2.74% during 2025-2035, Impelled by Development of Long-Acting Bronchodilators, Combination Inhalers, and Biologics ...